[1]
|
D. S. Martin, R. L. Stolfi, R. C. Sawyer and C. W. Young, “Application of Biochemical modulation with a Therapeutically Inactive Modulating Agent in Clinical Trials of Cancer Chemotherapy,” Cancer Treatment Report, Vol. 69, No. 4, 1985, pp. 421-423.
|
[2]
|
B. Leyland-Jones and P. J. O’Dwyer, “Biochemical Modulation: Application of Labolatory Models to the Clinic,” Cancer Treatment Report, Vol. 70, No. 1, 1986, pp. 219-229.
|
[3]
|
J. R. Bertino, W. L. Sawicki, C. A. Lindquist and V. S. Gupta, “Schedule-Dependent Antitumor Effects of Methotrexate and 5-Fluorouracil,” Cancer Research, Vol. 37, No. 1, 1977, pp. 327-328.
|
[4]
|
C. Tournigand et al., “FOLFIRI followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study,” Journal of Clinical Oncology, Vol. 22, No. 2, 2004, pp. 229-237.
doi:10.1200/JCO.2004.05.113
|
[5]
|
F. Maindrault-Goebe et al., “High-dose Intensity Oxaliplatin Added to the Simplified Bimonthly Leucovorin and 5-Fluorouracil Regimen as Second-Line Therapy for Metastatic Colorectal Cancer (FOLFOX 7),” European Journal of Cancer, Vol. 37, No. 8, 2001, pp. 1000-1005.
doi:10.1016/S0959-8049(01)00068-5
|
[6]
|
J. C. Bendell, et al., “Randomized Phase II Study of Perifosine in combination with Capecitabine (P-CAP) versus Capecitabine Plus Placebo (CAP) in Patients with second- or Third-line Metastatic Colon Cancer (mCRC): Updated Results,” Gastrointestinal Cancers Symposium, Orland, 22-24 January 2010.
|
[7]
|
M. Peeters, et al., “Randomized Phase III Study of Panitumumab (pmab) with FOLFIRI versus FOLFIRI Alone as Second-Line Treatment (tx) in Patients (pts) with Metastatic Colorectal Cancer (mCRC): Patient-Reported Outcomes (PRO),” Gastrointestinal Cancers Symposium, Orland, 22-24 January 2010.
|
[8]
|
V. Torchilin, “Recent Advances with Liposomes as Pharmaceutical Carriers,” Nature Reviews Drug Discovery, Vol. 4, No. 2, 2005, pp. 145-160. doi:10.1038/nrd1632
|
[9]
|
Y. Kakizawa and K. Kataoka, “Block Copolymer Micelles for Delivery of Gene and Related Compounds,” Advanced Drug Delivery Reviews, Vol. 54, No. 2, 2002, pp. 203-222.
doi:10.1016/S0169-409X(02)00017-0
|
[10]
|
M. Yokoyama, “Polymeric Micelles as a New Drug Carrier System and Their Required Considerations for Clinical Trials,” Expert Opinion on Drug Delivery, Vol. 7, No. 2, 2010, pp. 145-158. doi:10.1517/17425240903436479
|
[11]
|
C. Amin, N. Mackman, and N. S. Key, “Microparticles and Cancer,” Pathophysiology of Haemostasis and Thrombosis, Vol. 36, No. 3-4, 2008, pp. 177-183.
doi:10.1159/000175155
|
[12]
|
H. Maeda, T. Sawa and T. Konno, “Mechanism of Tumor-Targeted Delivery of Macromolecular Drugs, Including the EPR Effect in Solid Tumor and Clinical Overview of the Prototype Polymeric Drug SMANCS,” Journal of Controlled Release, Vol. 74, No. 1-3, 2001, pp. 47-61.
doi:10.1016/S0168-3659(01)00309-1
|
[13]
|
N. D. James, et al., “Liposomal Doxorubicin (Doxil): An Effective New Treatment for Kaposi’s Sarcoma in AIDS,” Clinical oncology, Vol. 6, No. 5, 1994, pp. 294-296.
doi: 10.1016/S0936-6555(05)80269-9
|
[14]
|
S. de Marie, R. Janknegt, and I. A. Bakker-Woudenberg, “Clinical Use of Liposomal and Lipid-Complexed Amphotericin B,” The Journal of Antimicrobial Chemotherapy, Vol. 33, No. 5, 1994, pp. 907-916.
|doi:10.1093/jac/33.5.907
|
[15]
|
M. Harries, P. Ellis and P. Harper, “Nanoparticle Albumin-Bound Paclitaxel for Metastatic Breast Cancer,” Journal of clinical oncology, Vol. 23, No. 31, 2005, pp. 7768-7771. doi:10.1200/JCO.2005.08.002
|
[16]
|
F. Greco and M. J. Vicent, “Combination Therapy: Opportunities and Challenges for Polymer-Drug Conjugates as Anticancer Nanomedicines,” Advanced Drug Delivery Reviews, Vol. 61, No. 13, 2009, pp. 1203-1213.
doi:10.1016/j.addr.2009.05.006
|
[17]
|
C.-M. J. Hu, S. Aryal and L. Zhang, “Nanoparticle-Assisted Combination Therapies for Effective Cancer Treatment,” Therapeutic Delivery, Vol. 1, No. 2, 2010, pp. 323-334. doi:10.4155/tde.10.13
|
[18]
|
H. Zhang, G. Wang, and H. Yang, “Drug Delivery Systems for Differential Release in Combination Therapy,” Expert Opinion on Drug Delivery, Vol. 8, No. 2, 2011, pp. 171-190. doi:10.1517/17425247.2011.547470
|
[19]
|
L. Santucci, et al., “Nitric Oxide Modulates Proapoptotic and Antiapoptotic Properties of Chemotherapy Agents: The Case of NO-Pegylated Epirubicin,” The FASEB Journal, Vol. 20, No. 6, 2006, pp. 765-767.
doi:10.1096/fj.05-4452fje
|
[20]
|
G. Pasut, et al., “Polymer-Drug Conjugates for Combination Anticancer Therapy: Investigating the Mechanism of Action,” Journal of Medicinal Chemistry, Vol. 52, No. 20, 2009, pp. 6499-6502. doi:10.1021/jm900804m
|
[21]
|
Q. Wu, R. Kreienberg and I. B. Runnebaum, “Growth Suppression of Human Ovarian Carcinoma OV-MZ-2a and OV-MZ-32 Cells Mediated by Gene Transfer of Wild-Type p53 Enhanced by Chemotherapy in Vitro,” Journal of Cancer Research and Clinical Oncology, Vol. 126, No. 3, 2000, pp. 139-144. doi:10.1007/s004320050023
|
[22]
|
N. Wiradharma, Y. W. Tong and Y. Y. Yang, “Self-Assembled Oligopeptide Nanostructures for Co-Delivery of Drug and Gene with Synergistic Therapeutic Effect,” Biomaterials, Vol. 30, No. 17, 2009, pp. 3100-3109.
doi: 10.1016/j.biomaterials.2009.03.006
|
[23]
|
S. Shin, et al., “An anti-Apoptotic Protein Human Survivin Is a Direct Inhibitor of Caspase-3 and -7,” Biochemistry, Vol. 40, No. 4, 2001, pp. 1117-1123.
doi:10.1021/bi001603q
|
[24]
|
A. Chandele, V. Prasad, J. C. Jagtap, R. Shukla and P. R. Shastry, “Upregulation of Survivin in G2/M Cells and Inhibition of Caspase 9 Activity Enhances Resistance in Staurosporine-Induced Apoptosis,” Neoplasia, Vol. 6, No. 1, 2004, pp. 29-40.
|
[25]
|
J. C. Reed, “The Survivin Saga Goes in Vivo,” The Jour- nal of Clinical Investigation, Vol. 108, No. 7, 2001, pp. 965-969. doi:10.1172/JCI14123
|
[26]
|
W. Xiao, X. Chen, L. Yang, Y. Mao, Y. Wei and L. Chen, “Co-Delivery of Doxorubicin and Plasmid by a Novel FGFR-Mediated Cationic Liposome,” International Journal of Pharmaceutics, Vol. 393, No. 1-2, 2010, pp. 119-126. doi:10.1016/j.ijpharm.2010.04.018
|
[27]
|
Z. Xu, Z. Zhang, Y. Chen, L. Chen, L. Lin and Y. Li, “The Characteristics and Performance of a Multifunctional Nanoassembly System for the Co-Delivery of Docetaxel and iSur-pDNA in a Mouse Hepatocellular Carcinoma Model,” Biomaterials, Vol. 31, No. 5, 2010, pp. 916-922. doi:10.1016/j.biomaterials.2009.09.103
|
[28]
|
G. M. Tozer, C. Kanthou and B. C. Baguley, “Disrupting Tumour Blood Vessels,” Nature Reviews Cancer, Vol. 5, No. 6, 2005, pp. 423-435. doi:10.1038/nrc1628
|
[29]
|
Y.-F. Zhang, J.-C. Wang, D.-Y. Bian, X. Zhang and Q. Zhang, “Targeted Delivery of RGD-Modified Liposomes Encapsulating both Combretastatin A-4 and Doxorubicin for Tumor Therapy: In Vitro and in Vivo Studies,” European Journal of Pharmaceutics and Biopharmaceutics, Vol. 74, No. 3, 2010, pp. 467-473.
doi:10.1016/j.ejpb.2010.01.002
|
[30]
|
Z. Wang and P. C. Ho, “A Nanocapsular Combinatorial Sequential Drug Delivery System for Antiangiogenesis and Anticancer Activities,” Biomaterials, Vol. 31, No. 27, 2010, pp. 7115-7123.
doi:10.1016/j.biomaterials.2010.05.075
|
[31]
|
T. Yang, et al., “Targeted Delivery of a Combination Therapy Consisting of Combretastatin A4 and Low-Dose Doxorubicin against Tumor Neovasculature,” Nanomedicine: nanotechnology, biology, and medicine, 2011, in press.
doi:10.1016/j.nano.2011.05.003
|
[32]
|
D. Ingber, et al., “Synthetic Analogues of Fumagillin that Inhibit Angiogenesis and Suppress Tumour Growth,” Nature, Vol. 348, No. 6301, 1990, pp. 555-557.
doi:10.1038/348555a0
|
[33]
|
R. Satchi-Fainaro, et al., “Targeting Angiogenesis with a Conjugate of HPMA Copolymer and TNP-470” Nature Medicine, Vol. 10, No. 3, 2004, pp. 255-261.
doi:10.1038/nm1002
|
[34]
|
E. Segal, et al., “Targeting Angiogenesis-Dependent Calcified Neoplasms Using Combined Polymer Therapeutics,” PloS One, Vol. 4, No. 4, 2009, p. e5233.
doi:10.1371/journal.pone.0005233
|
[35]
|
C. Zhu, et al., “Co-Delivery of siRNA and Paclitaxel into Cancer Cells by Biodegradable Cationic Micelles Based on PDMAEMA-PCL-PDMAEMA Triblock Copolymers,” Bioma-terials, Vol. 31, No. 8, 2010, pp. 2408-2416.
doi:10.1016/j.biomaterials.2009.11.077
|
[36]
|
H.-Y. Huang, W.-T. Kuo, M.-J. Chou and Y.-Y. Huang, “Co-Delivery of Anti-Vascular Endothelial Growth Factor siRNA and Doxorubicin by Multifunctional Polymeric Micelle for Tumor Growth Suppression,” Journal of Biomedical Materials Re-search Part A, Vol. 97, No. 3, 2011, pp. 330-338. doi:10.1002/jbm.a.33055
|
[37]
|
J. Wang, et al., “In Vitro Cytotoxicity of Stealth Lipo- somes Co-Encapsulating Doxorubicin and Verapamil on Doxorubicin-Resistant Tumor Cells,” Biological & Pharmaceutical Bulletin, Vol. 28, No. 5, 2005, pp. 822-828.
doi:10.1248/bpb.28.822
|
[38]
|
J. Wu, et al., “Reversal of Multidrug Resistance by Transferrin-Conjugated Liposomes Co-Encapsulating Doxorubicin and Verapamil,” Journal of Pharmacy & Pharmaceutical Sciences, Vol. 10, No. 3, 2007, pp. 350-357.
|
[39]
|
Z. Liu, X. Y. Wu and R. Bendayan, “In Vitro Investigation of Ionic Polysaccharide Microspheres for Simultaneous Delivery of Chemosensitizer and Antineoplastic Agent to Multidrug-Resistant Cells,” Journal of Pharmaceutical Sciences, Vol. 88, No. 4, 1999, pp. 412-418.
doi:10.1021/js9803353
|
[40]
|
C. E. Soma, C. Dubernet, D. Bentolila, S. Benita and P. Couvreur, “Reversion of Multidrug Resistance by Co-Encapsulation of Doxorubicin and Cyclosporin A in Polyalkylcyanoacrylate Nanoparticles,” Biomaterials, Vol. 21, No. 1, 2000, pp. 1-7. doi:10.1016/S0142-9612(99)00125-8
|
[41]
|
X. Song, et al., “PLGA Nanoparticles Simultaneously Loaded with Vincristine Sulfate and Verapamil Hydrochloride: Systematic Study of Particle Size and Drug Entrapment Efficiency,” International Journal of Pharmaceutics, Vol. 350, No. 1-2, 2008, pp. 320-329.
doi:10.1016/j.ijpharm.2007.08.034
|
[42]
|
X. R. Song, et al., “Reversion of Multidrug Resistance by Co-Encapsulation of Vincristine and Verapamil in PLGA Nanoparticles,” European Journal of Pharmaceutical Sciences, Vol. 37, No. 3-4, 2009, pp. 300-305.
doi:10.1016/j.ejps.2009.02.018
|
[43]
|
Y. Patil, T. Sadhukha, L. Ma and J. Panyam, “Nanoparticle-Mediated Simultaneous and Targeted Delivery of Paclitaxel and Tariquidar Overcomes Tumor Drug Resistance,” Journal of Controlled Release, Vol. 136, No. 1, 2009, pp. 21-29. doi:10.1016/j.jconrel.2009.01.021
|
[44]
|
H. L. Wong, R. Bendayan, A. M. Rauth and X. Y. Wu, “Development of Solid Lipid Nanoparticles Containing Ionically Complexed Chemotherapeutic Drugs and Chemosensitizers,” Journal of Pharmaceutical Sciences, Vol. 93, No. 8, 2004, pp. 1993-2008. doi:10.1002/jps.20100
|
[45]
|
H. L. Wong, R. Bendayan, A. M. Rauth and X. Y. Wu, “Simultaneous Delivery of Doxorubicin and GG918 (Elacridar) by New Polymer-Lipid Hybrid Nanoparticles (PLN) for Enhanced Treatment of Multidrug-Resistant Breast Cancer,” Journal of Controlled Release, Vol. 116, No. 3, 2006, pp. 275-284. doi:10.1016/j.jconrel.2006.09.007
|
[46]
|
R. I. Pakunlu, Y. Wang, M. Saad, J. J. Khandare, V. Starovoytov and T. Minko, “In Vitro and in Vivo Intracellular Liposomal Delivery of Antisense Oligonucleotides and Anticancer Drug,” Journal of controlled release, Vol. 114, No. 2, 2006, pp. 153-162.
doi: 0.1016/j.jconrel.2006.06.010
|
[47]
|
X.-B. Xiong and A. Lavasanifar, “Traceable Multifunctional Micellar Nanocarriers for Cancer-Targeted Co-Delivery of MDR-1 siRNA and Doxorubicin,” ACS Nano, Vol. 5, No. 6, 2011, pp. 5202-5213. doi:10.1021/nn2013707
|
[48]
|
S. Sengupta, et al., “Temporal Targeting of Tumour Cells and Neovasculature with a Nano-scale Delivery System,” Nature, Vol. 436, No. 7050, 2005, pp. 568-572.
doi:10.1038/nature03794
|
[49]
|
H. Nie, Z. Dong, D. Y. Arifin, Y. Hu and C.-H. Wang, “Core/Shell Microspheres via Coaxial Electrohydrodynamic Atomization for Sequential and parallel Release of Drugs,” Journal of Biomedical Materials Research Part A, Vol. 95, No. 3, 2010, pp. 709-716.
doi:10.1002/jbm.a.32867
|
[50]
|
X. Hao, et al., “Angiogenic Effects of Sequential Release of VEGF-A165 and PDGF-BB with Alginate Hydrogels after Myocardial Infarction,” Cardiovascular Research, Vol. 75, No. 1, 2007, pp. 178-185.
doi:10.1016/j.cardiores.2007.03.028
|
[51]
|
A. T. Raiche and D. A. Puleo, “In Vitro EFfects of Combined and Sequential Delivery of Two Bone Growth Factors,” Biomaterials, Vol. 25, No. 4, 2004, pp. 677-685.
doi:10.1016/S0142-9612(03)00564-7
|
[52]
|
R. R. Chen, E. A. Silva, W. W. Yuen and D. J. Mooney, “Spatio-Temporal VEGF and PDGF Delivery Patterns Blood Vessel Formation and Maturation,” Pharmaceutical Research, Vol. 24, No. 2, 2007, pp. 258-264.
doi:10.1007/s11095-006-9173-4
|
[53]
|
C. Strobel, N. Bormann, A. Kadow-Romacker, G. Schmi- dmaier and B. Wildemann, “Sequential Release Kinetics of Two (Gentamicin and BMP-2) or Three (Gentamicin, IGF-I and BMP-2) Substances from a One-Component Polymeric Coating on Implants,” Journal of Controlled Release, Vol. 156, No. 1, 2011, pp. 37-45.
doi:10.1016/j.jconrel.2011.07.006
|
[54]
|
F. B. Basmanav, G. T. Kose and V. Hasirci, “Sequential Growth Factor Delivery from Complexed microspheres for Bone Tissue Engineering,” Biomaterials, Vol. 29, No. 31, 2008, pp. 4195-4204.
doi:10.1016/j.biomaterials.2008.07.017
|
[55]
|
P. Yilgor, K. Tuzlakoglu, R. L. Reis, N. Hasirci and V. Hasirci, “Incorporation of a Sequential BMP-2/BMP-7 Delivery System into Chitosan-Based Scaffolds for Bone Tissue Engineering,” Biomaterials, Vol. 30, No. 21, 2009, pp. 3551-3559. doi:10.1016/j.biomaterials.2009.03.024
|
[56]
|
Q. Sun, et al., “Sustained Release of Multiple Growth Factors from Injectable Polymeric System as a Novel Therapeutic Approach towards Angiogenesis,” Pharmaceutical Research, Vol. 27, No. 2, 2010, pp. 264-271.
doi:10.1007/s11095-009-0014-0
|
[57]
|
J. A. MacDiarmid, et al., “Sequential Treatment of Drug- Resistant Tumors with Targeted Minicells Containing siRNA or a Cytotoxic Drug,” Nature biotechnology, Vol. 27, No. 7, 2009, pp. 643-651. doi:10.1038/nbt.1547
|
[58]
|
J. Jiangm, et al., “Sequential Treatment of Drug-Resistant Tumors with RGD-Modified Liposomes Containing siRNA or Doxorubicin,” European Journal of Pharmaceutics and Biopharmaceutics, Vol. 76, No. 2, 2010, pp. 170-178.
doi:10.1016/j.ejpb.2010.06.011
|
[59]
|
P. Yilgor, N. Hasirci and V. Hasirci, “Sequential BMP-2/ BMP-7 Delivery from Polyester Nanocapsules,” Journal of Biomedical Materials Research Part A, Vol. 93, No. 2, 2010, pp. 528-536. doi:10.1002/jbm.a.32520
|
[60]
|
J. E. Tengood, K. M. Kovach, P. E. Vescovi, A. J. Russell and S. R. Little, “Sequential Delivery of Vascular Endothelial Growth Factor and Sphingosine 1-Phosphate for Angiogenesis,” Biomaterials, Vol. 31, No. 30, 2010, pp. 7805-7812. doi:10.1016/j.biomaterials.2010.07.010
|
[61]
|
W. Xia, J. Chang, J. Lin and J. Zhu, “The pH-Controlled Dual-Drug Release from Mesoporous Bioactive Glass/ Polypeptide Graft Copolymer Nanomicelle Composites,” European Journal of Pharmaceutics and Biopharmaceutics, Vol. 69, No. 2, 2008, pp. 546-552.
doi:10.1016/j.ejpb.2007.11.018
|
[62]
|
L. Wei, C. Cai, J. Lin and T. Chen, “Dual-Drug Delivery System Based on Hydrogel/Micelle Composites,” Bio-materials, Vol. 30, No. 13, 2009, pp. 2606-2613.
doi:10.1016/j.biomaterials.2009.01.006
|
[63]
|
T. Okuda, K. Tominaga and S. Kidoaki, “Time-Programmed Dual Release Formulation by Multilayered Drug-Loaded Nanofiber Meshes,” Journal of Controlled Release, Vol. 143, No. 2, 2010, pp. 258-264.
doi:10.1016/j.jconrel.2009.12.029
|
[64]
|
A. S. Barbas, J. Mi, B. M. Clary and R. R. White, “Aptamer Applications for Targeted Cancer Therapy,” Future Oncology, Vol. 6, No. 7, 2010, pp. 1117-1126.
doi:10.2217/fon.10.67
|
[65]
|
X.-B. Xiong and A. Lavasanifar, “Traceable Multifunctional Micellar Nanocarriers for Cancer-Targeted Co-Delivery of MDR-1 siRNA and Doxorubicin,” ACS Nano, Vol. 5, No. 6, 2011, pp. 5202-5213.
doi:10.1021/nn2013707
|
[66]
|
A. Singh, F. Dilnawaz, S. Mewar, U. Sharma, N. R. Jagannathan and S. K. Sahoo, “Composite Polymeric Magnetic Nanoparticles for Co-Delivery of Hydrophobic and Hydrophilic Anticancer Drugs and MRI Imaging for Cancer Therapy,” ACS Applied Materials & Interfaces, Vol. 3, No. 3, 2011, pp. 842-856. doi:10.1021/am101196v
|
[67]
|
C.-C. Huang, W. Huang and C.-S. Yeh, “Shell-by-Shell Synthesis of Multi-Shelled Mesoporous Silica Nanospheres for Optical Imaging and Drug Delivery,” Biomaterials, Vol. 32, No. 2, 2011, pp. 556-564.
doi: 0.1016/j.biomaterials.2010.08.114
|